Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

super-copper-announces-initiation-of-research-coverage-by-baader-europe

Super Copper Announces Initiation of Research Coverage by Baader Europe

Mar 17, 2026

This is a paid press release. Contact the press release distributor directly with any inquiries. CNW Group Tue,…

Read more
this-ingredion-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-tuesday-–-bioxcel-therapeutics-(nasdaq:btai),-ingredion-(nyse:ingr)

This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday – BioXcel Therapeutics (NASDAQ:BTAI), Ingredion (NYSE:INGR)

Mar 17, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
william-blair-maintains-outperform-for-par-technology-corporation-(par)-mar-2026

William Blair Maintains Outperform for PAR Technology Corporation (PAR) Mar 2026

Mar 17, 2026

On March 13, 2026, William Blair maintained an Outperform rating on PAR Technology Corporation (PAR) and cited the…

Read more
ubs-maintains-neutral-on-the-buckle,-inc.-(bke)-march-16,-2026;-pt-cut-to-$53

UBS Maintains Neutral on The Buckle, Inc. (BKE) March 16, 2026; PT Cut to $53

Mar 17, 2026

On March 16, 2026, UBS maintained a Neutral rating on The Buckle, Inc. (BKE) and lowered its price…

Read more
ubs-maintains-neutral-on-petco-health-&-wellness-co,-inc.-(woof)-mar-16,-2026

UBS Maintains Neutral on Petco Health & Wellness Co., Inc. (WOOF) Mar 16, 2026

Mar 17, 2026

Get analyst ratings, AI forecasts, and market updates in your inbox every morning. ~15% average open rate and…

Read more
cowen-keeps-skin-at-hold,-cuts-pt-to-$1.50-mar-16-2026-the-beauty-health-company

Cowen Keeps SKIN at Hold, Cuts PT to $1.50 Mar 16 2026 The Beauty Health Company

Mar 17, 2026

Cowen kept The Beauty Health Company (SKIN) at Hold on March 16, 2026, while lowering its price target…

Read more
william-blair-maintains-outperform-on-dianthus-therapeutics-(dnth)-march-2026

William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026

Mar 17, 2026

William Blair maintained an Outperform rating on Dianthus Therapeutics, Inc. (DNTH) on March 16, 2026, and that decision…

Read more
leerink-maintains-outperform-on-eldn-(eledon-pharmaceuticals)-march-16,-2026

Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026

Mar 17, 2026

Leerink Partners reiterated an Outperform rating on Eledon Pharmaceuticals, Inc. (ELDN) on March 16, 2026, keeping its view…

Read more
jefferies-maintains-buy-on-anro,-pt-raised-to-$35-on-mar-16,-2026

Jefferies Maintains Buy on ANRO, PT Raised to $35 on Mar 16, 2026

Mar 17, 2026

Jefferies maintained a Buy rating on Alto Neuroscience, Inc. (ANRO) on March 16, 2026, while raising its price…

Read more
public-storage-(psa):-william-blair-outperform;-bmo-capital-market-perform-mar16

Public Storage (PSA): William Blair Outperform; BMO Capital Market Perform Mar16

Mar 17, 2026

On Mar 16, 2026 William Blair reiterated Outperform on Public Storage (PSA) while BMO Capital maintained Market Perform,…

Read more
why-this-analyst-is-still-pounding-the-table-on-amd-stock

Why This Analyst Is Still Pounding the Table on AMD Stock

Mar 17, 2026

Ai chip by Quality Stock Arts via Shutterstock Advanced Micro Devices (AMD) has been among the hottest stocks…

Read more
hc.-wainwright-maintains-buy-on-novabridge-biosciences-(nbp)-mar-16,-2026

H.C. Wainwright Maintains Buy on NovaBridge Biosciences (NBP) Mar 16, 2026

Mar 17, 2026

H.C. Wainwright maintained a Buy on NovaBridge Biosciences (NBP) on March 16, 2026, keeping a $9 price target…

Read more
  1. Pages:
  2. «
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. 9
  12. ...
  13. 377
  14. »

Posts pagination

Newer posts Page 1 … Page 6 … Page 377 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.